| Literature DB >> 36008739 |
Qi Chen1, Li Yao1, Qian Wu1, Jianguo Xu1, Chao Yan1, Chuanxiang Guo2, Chao Zhang2, Tao Xu3, Panzhu Qin4,5, Wei Chen6,7.
Abstract
A biosensor for rapid and simultaneous visual identification of high-risk human papillomavirus (HPV) genotypes 16 and 18 in clinical samples based on polymerase chain reaction (PCR) integrated lateral flow strip platform was developed. Using an one-step protocol to extract nucleic acid rapidly and the functionalized primer sets specific to HPV-16 and 18 were designed for the simultaneous amplification. In the presence of target HPV genotypes, the corresponding functionalized primer sets will participate in the PCR process and produce numerous duplex functionalized dsDNA amplicons. With the bridge effect of duplex functionalized dsDNA amplicons between gold nanoparticles-fluorescein isothiocyanate antibody conjugates (AuNP-FITC antibody conjugates) and other two antibodies on corresponding test line (T1 or T2), visualized color signals on test lines could be obtained directly visible with a naked eye. Combining the high amplification efficiency of PCR and the visualized sensing of LFS, as low as 700 copies of HPV-16 and 18 DNA were detected simultaneously within 75 min, which can promote application in the resource limited settings. High-risk genotypes of HPV-16 and HPV-18 were easily and simultaneously screened with the amplification-assisted molecular lateral flow strip by on-site observation in the resource-limited settings.Entities:
Keywords: Human papillomavirus; Molecular amplification; Nucleic acid lateral flow strip; Rapid screening; Two-cancer screening; Visualized sensing
Mesh:
Substances:
Year: 2022 PMID: 36008739 PMCID: PMC9409624 DOI: 10.1007/s00604-022-05449-5
Source DB: PubMed Journal: Mikrochim Acta ISSN: 0026-3672 Impact factor: 6.408
Fig. 1(I) The schematic diagram of rapid and simultaneous identification of HPV-16 and HPV-18; (II) the schematic principle of the lateral flow strip for simultaneous detection of amplicons of HPV-16 and HPV-18
Fig. 2Feasibility verification results. Left image: illustration of agarose gel electrophoresis (AGE) verification (M: maker; 1: blank control; 2: negative sample; 3: HPV-16 positive sample; 4: blank control; 5: negative sample; 6: HPV-18 positive sample). Right image: results of LFS verification, the first three LFS were used to detect the HPV-16, and the last three LFS were used to detect the HPV-18. (FPHPV18: forward primer of HPV-18; RPHPV18: reverse primer of HPV-18; FPHPV16: forward primer of HPV-16; RPHPV16: reverse primer of HPV-16; THPV18: template of HPV-18; THPV16: template of HPV-16. Green circle means with the presence of the component; empty circle means without the component)
Fig. 3Illustration of the designed protocol’s sensitivity: the results at different concentrations of HPV-16 and HPV-18; left panel: results of agarose gel electrophoresis to decreasing concentrations of HPV-16 and increasing concentrations of HPV-18; right panel: results of LFS to decreasing concentrations of HPV-16 and increasing concentrations of HPV-18; and the quantitative analysis of the LFS results with ImageJ
An overview of recent reported nanomaterial-based methods for the detection of HPV-16/18
| Methods | Materials used | LOD | Target | Technique | DNA extraction time and conditions | Reference |
|---|---|---|---|---|---|---|
| Molecular amplification integrated lateral flow strip platform | AuNPs | 7 | HPV-16 and 18 | Colorimetric | 5 min, room temperature | This work |
| A fully integrated paper fluidic molecular diagnostic chip | AuNPs | 104 copies | HPV-16 | Colorimetric | 10–15 min, room temperature | [ |
| PCR-immunochromatographic | AuNPs | 102 copies | HPV-16 and 18 | Colorimetric | 40 min, room temperature | [ |
| CRISPR-Cas12a with lateral-flow strip | AuNPs | HPV-16 170.6 copies/μL HPV-18 151.8 copies/μL | HPV-16 or 18 | Dolorimetric | 5 min, 95 °C | [ |
| PCR and fluorescence DNA chip | FL beads | / | HPV-16 or 18 | Fluorescence | ≥ 25 min, variable temperature | [ |
Fig. 4Specificity study of the amplification and LFS. (Mixture of HPV-16 and HPV-18, HPV-16, HPV-18, and other 18 types of HPV were selected to verify the specificity of the designed protocol)
Fig. 5The detection results of HPV-16/18 in actual clinic samples with amplification-assisted molecular LFS